Complete Remission of a Diffuse Large B-Cell Lymphoma in a Young Patient, with Severe Tuberous Sclerosis, Treated with Metronomic Chemotherapy and Ibrutinib: A Case Report
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Complete Remission of a Diffuse Large B-Cell Lymphoma in a Young Patient, with Severe Tuberous Sclerosis, Treated with Metronomic Chemotherapy and Ibrutinib: A Case Report
Authors
Keywords
-
Journal
CHEMOTHERAPY
Volume -, Issue -, Pages 1-5
Publisher
S. Karger AG
Online
2023-08-08
DOI
10.1159/000533236
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
- (2022) Marta Banchi et al. Journal of Clinical Medicine
- Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma
- (2022) Guido Bocci et al. Journal of Clinical Medicine
- Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds
- (2021) Maria Christina Cox et al. CANCER LETTERS
- All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma
- (2020) Maria Christina Cox et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
- (2019) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis
- (2019) Joost S. Vermaat et al. HAEMATOLOGICA
- The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma
- (2019) M. Christina Cox et al. INVESTIGATIONAL NEW DRUGS
- MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications
- (2019) Ruben A.L. de Groen et al. HAEMATOLOGICA
- Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
- (2018) Gianfranco Natale et al. CANCER LETTERS
- Tuberous sclerosis complex is required for tumor maintenance in MYC‐driven Burkitt's lymphoma
- (2018) Götz Hartleben et al. EMBO JOURNAL
- Ibrutinib inhibits pre-BCR+B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK
- (2016) Ekaterina Kim et al. BLOOD
- Adolescent and young adult non-Hodgkin lymphoma
- (2016) Jessica Hochberg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
- (2016) Guido Bocci et al. Nature Reviews Clinical Oncology
- Clinical response to everolimus in a patient with Hodgkin’s lymphoma harboring a TSC2 mutation
- (2016) G F Perini et al. Blood Cancer Journal
- MYC in DLBCL: partners matter
- (2015) E. Campo BLOOD
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens
- (2014) K Hohloch et al. LEUKEMIA
- Tuberous sclerosis
- (2008) Paolo Curatolo et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started